Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amylin Pharmaceuticals, a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialisation of medicines, has reported revenues of $164.4m for the second quarter ended June 30, 2010, compared to $198.6m for the comparable period in 2009.
Subscribe to our email newsletter
Amylin Pharma has posted a net loss, excluding a restructuring charge of $3.4m. Non-GAAP operating loss was $7.4m, a 67% improvement compared to $22.4m for the same period in 2009. Operating income was $38.6m, compared to $58.1m for the comparable period in 2009.
Amylin Pharma’s total revenues for the six months ended June 30, 2010 were $338.5m. This includes net product sales of $334.8m, including $290.5m for Byetta and $44.3m for Symlin. This compares to net product sales of $376.8m, consisting of $332.8m for Byetta and $44m for Symlin for the same period in 2009.
Daniel Bradbury, president and CEO of Amylin Pharma, said: “We achieved several important milestones in the Bydureon development program during the second quarter and continue to position the company for long-term value creation.
“As we move into the second half of 2010, we will remain focused on our goal of achieving sustainable operational cash flow by the end of the year, while also preparing for the anticipated approval and successful market introduction of Bydureon.”